510(k) device
cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 Systems
Roche Molecular Systems, Inc. · Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF, Class II) · First FDA decision Jul 27, 2023, newest Jul 31, 2025COVID-19, flu and respiratory infections
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
19
Naming "cobas"
MAUDE reports
27,616
Brand "cobas", since 2015
PubMed studies
4,678
Mentioning "cobas"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing cobas Respiratory 4-flex for use on the cobas 5800/6800/8800 Systems
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K243455 · Decided Jul 31, 2025 · 266 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Erythropoiesis Stimulating Agents (ESAs) for Treatment of Anemia in Adults with CKD Including Patients on Dialysis and Patients not on DialysisNational analysisReview closedCAG-00413NUpdated Sep 17, 2026
- Prolotherapy, Joint Sclerotherapy, and Ligamentous Injections with Sclerosing AgentsNational determinationOn the books150.7Updated Aug 17, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "cobas", any status and sponsor, newest update first.
- Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General PractitionerPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT02749110 · 308 participants · Start Aug 28, 2016 · Primary completion Aug 23, 2019
Device: Vaginal self-sampling brush · For: Malignant Tumor of Cervix; Cervical Intraepithelial Neoplasia
Sites: Herzeele, France
18 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "cobas", and for the whole product code for context.
This brand
27,616 reports: 27,470 malfunction, 131 injury, 7 death
Whole product code QOF
56 reports: 48 malfunction, 8 injury, 0 death
Newest reports for this brand
- cobas 6000 c501 moduleMalfunction
1823260-2026-04488 · Received Oct 29, 2026 · Event dated Oct 6, 2026
Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Device problem as coded: High Test Results
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "cobas"[tiab]. The summary above synthesizes these.
- Profile of Roche's cobas® HCV tests.
Kessler HH, Stelzl E · Expert Rev Mol Diagn · 2017Review
- Clinical Performance of the cobas Liat SARS-CoV-2 & Influenza A/B Assay in Nasal Samples.
Akashi Y, Horie M, Kiyotaki J, et al. · Mol Diagn Ther · 2022Research Support, Non-U.S. Gov't
- Applicability of the cobas 6800 System for Epstein-Barr viral load quantitation using whole-blood specimens.
Song J, Kim S, Kwak E, et al. · Am J Clin Pathol · 2024
- Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY, Schlag PA, Karwowska SM, et al. · PLoS One · 2023
- Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation.
Jackson K, Bonanzinga S, Edwards R, et al. · J Med Virol · 2022Research Support, Non-U.S. Gov't
- Performance evaluation of the cobas SARS-CoV-2 Duo, a novel qualitative and quantitative assay, for the detection of SARS-CoV-2 RNA.
Su Y-D, Lai C-C, Lin T-H, et al. · Microbiol Spectr · 2023
- Possible False Results With cobas® EGFR Mutation Test v2 and Oncomine Dx Target Test for EGFR Mutation.
Kanaoka K, Tamiya A, Inagaki Y, et al. · Anticancer Res · 2023
- Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance.
de Vos M, David A, Duraisamy K, et al. · J Mol Diagn · 2024
- Evaluation of cobas Influenza A/B & RSV Test for Diagnosis of Equine Influenza.
Nemoto M, Okita N, Kitahata M, et al. · J Equine Vet Sci · 2020
- Performance evaluation of fully automated cobas® 6800 CMV PCR for the detection and quantification of cytomegalovirus DNA in neonatal urine and saliva, and adult urine, saliva, and vaginal secretion.
Tan NK, Pope CF, Carrington D · J Med Virol · 2023Research Support, Non-U.S. Gov't
- Diagnostic performance of the Cobas MTB and Logix Smart MTB for diagnosing pulmonary and extrapulmonary tuberculosis: a cross-sectional study of diagnostic tests.
Hueda-Zavaleta M, Gomez de la Torre JC, Minchón-Vizconde D, et al. · Ther Adv Infect Dis · 2024
- Validation of the cobas 6800 human papillomavirus test in primary cervical screening.
Sundström K, Lamin H, Dillner J · PLoS One · 2021Comparative Study, Research Support, Non-U.S. Gov't
Other devices of this type
Also filed under product code QOF.
- Xpert Xpress CoV-2/Flu plusCepheid® · 510(k) 2026
- BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel MiniBiofire Diagnostics, LLC · 510(k) 2025
- QIAstat-Dx Respiratory Panel PlusQIAGEN GmbH · 510(k) 2025
- Panther Fusion SARS-CoV-2/Flu A/B/RSV assayHologic, Inc. · 510(k) 2024
- BIOFIRE Respiratory Panel 2.1 (RP2.1)Biofire Diagnostics · De Novo 2026
- FINDER Flu A&B/SARS-CoV-2 TestBaebies, Inc. · 510(k) 2026
- Simplexa COVID-19/ Flu A/B & RSV Direct (MOL4450)Diasorin Molecular, LLC · 510(k) 2025
- cobas liat SARS-CoV-2 & Influenza A/B v2 nucleic acid testRoche Molecular Systems, Inc. · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.